Pharming Group (OTCMKTS:PHGUF) Announces Quarterly Earnings Results

Pharming Group (OTCMKTS:PHGUF) released its quarterly earnings results on Thursday. The biotechnology company reported $0.01 EPS for the quarter, reports. The firm had revenue of $106.50 million for the quarter, compared to analyst estimates of $89.72 million. Pharming Group had a return on equity of 1.12% and a net margin of 0.71%.

Pharming Group Stock Performance

PHGUF opened at $1.51 on Friday. The firm’s 50 day moving average is $1.77 and its 200-day moving average is $1.62. Pharming Group has a 52-week low of $0.79 and a 52-week high of $2.17. The company has a current ratio of 3.16, a quick ratio of 2.39 and a debt-to-equity ratio of 0.46.

About Pharming Group

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.